RMD Open (Feb 2024)

Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial

  • Merete Lund Hetland,
  • Hanne Lindegaard,
  • Oliver Hendricks,
  • Niels Steen Krogh,
  • Robin Christensen,
  • Mikkel Østergaard,
  • Mikael Boesen,
  • Ellen Margrethe Hauge,
  • Lykke Midtbøll Ørnbjerg,
  • Daniel Glinatsi,
  • Sabrina Mai Nielsen,
  • Kim Hørslev-Petersen,
  • Bo Ejbjerg,
  • Kristian Stengaard-Pedersen,
  • Ole Rintek Madsen,
  • Jan Alexander Villadsen,
  • Henrik Thomsen,
  • Signe Møller-Bisgaard,
  • Bente Jensen,
  • Jakob Møllenbach Møller

DOI
https://doi.org/10.1136/rmdopen-2023-003945
Journal volume & issue
Vol. 10, no. 1

Abstract

Read online

Objective To investigate whether a 2-year MRI treat-to-target strategy targeting the absence of osteitis combined with clinical remission, compared with a conventional treat-to-target strategy targeting clinical remission only (IMAGINE-rheumatoid arthritis (RA) trial) improves clinical and radiographic outcomes over 5 years in patients with RA in clinical remission.Methods IMAGINE-more was an observational extension study of the original 2-year IMAGINE-RA randomised trial (NCT01656278). Clinical examinations and radiographs (hands and feet) were obtained yearly. Prespecified coprimary outcomes at year 5 were Disease Activity Score in 28 joints C reactive protein (DAS28-CRP) remission rate (DAS28-CRP<2.6) and no radiographic progression (van der Heijde-modified Sharp score (vdHSS) ≤0) from baseline. Secondary outcomes included 5-year changes in radiographic, MRI and clinical measures of disease activity and physical function.Results In total 131 patients, 86 women (67%), mean age 61.2, disease duration 9.5 years, median baseline DAS28-CRP 1.9 (IQR 1.6–2.2) and vdHSS 16.0 (IQR 7.0–36.0) were included in the study; 59 (59%) patients from the original MRI treat-to-target group and 72 (72%) from the conventional group. At year 5, 47 patients (80%) in the MRI treat-to-target group vs 54 patients (75%) in the conventional treat-to-target group were in DAS28-CRP remission (OR 2.00 (95% CI 0.76 to 5.28); p=0.16) while 14 patients (24%) vs 19 patients (26%) had no radiographic progression (OR 0.70, (95% CI 0.28 to 1.71); p=0.43).Conclusion A 2-year combined MRI and clinical treat-to-target strategy, compared with a conventional clinical treat-to-target strategy alone, had no effect on the long-term probability of achieving DAS28-CRP remission and of avoiding radiographic progression.